Galenica : plans to divide the Group in the 4th quarter of 2016 01

Galenica plans to divide the Group in the 4th quarter of 2016

Tuesday, 1 December 2015, ↓ directly to download⁰¹

Since 1995, the Galenica Group has implemented its transformation strategy rigorously and with great success. In August 2014, the Board of Directors concluded that the Group was ready to prepare for a new phase, with the objective of developing the two Business units Vifor Pharma and Galenica Santé into two independent listed companies.
Both Business units, Vifor Pharma and Galenica Santé, have continued to develop successfully since then. Vifor Pharma in particular has attained a solid scale for independence, thanks to the pleasing growth in sales from its key products and the extension of its product portfolio. In fact, revenues are expected to break through the CHF 1 billon mark as early as 2016.
The Board of Directors of the Galenica Group has concluded that the preconditions have now been met for dividing the Group in the 4th quarter of 2016, provided there are no negative changes in the economic environment prior to that date. The preparatory work for this is moving ahead as scheduled.

Etienne Jornod carefully preparing planned handover of management

After successfully leading the Galenica Group for the last 20 years, Etienne Jornod has deemed the creation of two new companies as the right time to entrust the management of the company to new hands. He will continue to lead the Galenica Group as Executive Chairman until its division, and will be available afterwards in order to support his successors.

Read more⁰²

Galenica is a diversified Group active throughout the healthcare market which, among other activities, develops, manufactures and markets pharmaceutical products, runs pharmacies, provides logistical and database services and sets up networks. With its two Business units Vifor Pharma and Galenica Santé, the Galenica Group enjoys a leading position in all its core business activities. A large part of the Group's income is generated by international operations. Galenica is listed on the Swiss Stock Exchange (SIX Swiss Exchange, GALN, security number 1,553,646).